Document Detail

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration.
MedLine Citation:
PMID:  25441437     Owner:  NLM     Status:  In-Data-Review    
The US Food and Drug Administration currently accepts halving of glomerular filtration rate (GFR), assessed as doubling of serum creatinine level, as a surrogate end point for the development of kidney failure in clinical trials of kidney disease progression. A doubling of serum creatinine level generally is a late event in chronic kidney disease (CKD); thus, there is great interest in considering alternative end points for clinical trials to shorten their duration, reduce sample size, and extend their conduct to patients with earlier stages of CKD. However, the relationship between lesser declines in GFR and the subsequent development of kidney failure has not been well characterized. The National Kidney Foundation and Food and Drug Administration sponsored a scientific workshop to critically examine available data to determine whether alternative GFR-based end points have sufficiently strong relationships with important clinical outcomes of CKD to be used in clinical trials. Based on a series of meta-analyses of cohorts and clinical trials and simulations of trial designs and analytic methods, the workshop concluded that a confirmed decline in estimated GFR of 30% over 2 to 3 years may be an acceptable surrogate end point in some circumstances, but the pattern of treatment effects on GFR must be examined, specifically acute effects on estimated GFR. An estimated GFR decline of 40% may be more broadly acceptable than a 30% decline across a wider range of baseline GFRs and patterns of treatment effects on GFR. However, there are other circumstances in which these end points could lead to a reduction in statistical power or erroneous conclusions regarding benefits or harms of interventions. We encourage careful consideration of these alternative end points in the design of future clinical trials.
Andrew S Levey; Lesley A Inker; Kunihiro Matsushita; Tom Greene; Kerry Willis; Edmund Lewis; Dick de Zeeuw; Alfred K Cheung; Josef Coresh
Related Documents :
11036727 - Metal exposure among abrasive blasting workers at four u.s. air force facilities.
12959887 - Benzene exposure assessment for use of a mineral spirits-based degreaser.
16893837 - Personal dust exposures at a food processing facility.
7481727 - Validity criteria for exposure assessment methods.
24320017 - Identification of ethylene oxide in herbs, spices, and other dried vegetables imported ...
18848607 - Size-related consumption of scirpus maritimus tubers by greylag geese anser anser expla...
Publication Detail:
Type:  Journal Article     Date:  2014-10-16
Journal Detail:
Title:  American journal of kidney diseases : the official journal of the National Kidney Foundation     Volume:  64     ISSN:  1523-6838     ISO Abbreviation:  Am. J. Kidney Dis.     Publication Date:  2014 Dec 
Date Detail:
Created Date:  2014-12-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8110075     Medline TA:  Am J Kidney Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  821-35     Citation Subset:  IM    
Copyright Information:
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Adverse Technical Events in Home Hemodialysis.
Next Document:  GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Tre...